Применение моноклональных анти-CD20-антител в терапии лимфом в условиях пандемии COVID-19: за и против
https://doi.org/10.17650/1818-8346-2022-17-2-95-106
Аннотация
В настоящем обзоре представлены результаты сочетанного анализа данных литературы и собственных клинических наблюдений относительно безопасности и целесообразности применения моноклональных анти-CD20-антител в терапии B-клеточных лимфопролиферативных заболеваний в условиях пандемии новой коронавирусной инфекции COVID-19. Изложены основные моменты патогенеза влияния моноклональных анти-CD20-антител на течение COVID-19. Обобщены современные тенденции в модификации принятых алгоритмов терапии лимфопролиферативных заболеваний с включением моноклональных анти-CD20-антител, а также рассмотрены возможности специфической профилактики путем вакцинации против COVID-19.
Об авторах
К. А. Сычевская
ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России
Россия
Россия
125167 Москва, Новый Зыковский проезд, 4
С. К. Кравченко
ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России
Россия
Россия
125167 Москва, Новый Зыковский проезд, 4
Список литературы
1. Wang Q., Berger N.A., Xu R. Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection. JAMA Oncol 2021;7(2):220–7. DOI:10.1001/jamaoncol.2020.6178.
2. Grivas P., Khaki A.R., Wise-Draper T.M. et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol 2021;32(6):787–800. DOI:10.1016/j.annonc.2021.02.024.
3. Yang K., Sheng Y., Huang C. et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol 2020;21(7):904–13. DOI:10.1016/S1470-2045(20)30310-7.
4. Mehta V., Goel S., Kabarriti R. et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov 2020;10(7):935–41. DOI:10.1158/2159-8290.CD-20-0516.
5. Kuderer N.M., Choueiri T.K., Shah D.P. et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 2020;395(10241):1907–18. DOI:10.1016/S0140-6736(20)31187-9.
6. Lee L.Y.W., Cazier J.B., Starkey T. et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol 2020;21(10):1309–16. DOI:10.1016/S1470-2045(20)30442-3.
7. Dai M., Liu D., Liu M. et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov 2020;10(6):783–91. DOI:10.1158/2159-8290.CD-20-0422.
8. Martín-Moro F., Marquet J., Piris M. et al. Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. Br J Haematol 2020;190(1):e16–20. DOI:10.1111/bjh.16801.
9. Malard F., Genthon A., Brissot E. et al. COVID-19 outcomes in patients with hematologic disease. Bone Marrow Transplant 2020;55(11):2180–4. DOI:10.1038/s41409-020-0931-4.
10. He W., Chen L., Chen L. et al. COVID-19 in persons with haematological cancers. Leukemia 2020;34(6):1637–45. DOI:10.1038/s41375-020-0836-7.
11. Hatzl S., Eisner F., Schilcher G. et al. Response to “COVID-19 in persons with haematological cancers”. Leukemia 2020;34(8):2265–70. DOI:10.1038/s41375-020-0914-x.
12. Aries J.A., Davies J.K., Auer R.L. et al. Clinical outcome of coronavirus disease 2019 in haemato-oncology patients. Br J Haematol 2020;190(2):e64–7. DOI:10.1111/bjh.16852.
13. Wu Y., Chen W., Li W. et al. Clinical characteristics, therapeutic management, and prognostic factors of adult COVID-19 in patients with hematological malignancies. Leuk Lymphoma 2020;61(14):3440–50. DOI:10.1080/10428194.2020.1808204.
14. Niu A., Ning B., Socola F. et al. High mortality with high false negative rate: COVID-19 infection in patients with hematologic malignancies. Leuk Res 2021;106:106582. DOI:10.1016/j.leukres.2021.106582.
15. Maia C., Martín-Sánchez E., Garcés J.J. et al. Immunologic characterization of COVID-19 patients with hematological cancer. Haematologica 2020;106(5):1457–60. DOI:10.3324/haematol.2020.269878.
16. Lopez C.A., Chitty D., Chi J. et al. Outcomes in patients with hematological malignancies receiving anti-CD20 therapy in the setting of COVID-19 infection. Blood 2020;136:8–9. DOI:10.1182/blood-2020-143124.
17. Wood W.A., Neuberg D.S., Thompson J.C. et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv 2020;4(23):5966–75. DOI:10.1182/bloodadvances.2020003170.
18. Passamonti F., Cattaneo C., Arcaini L. et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol 2020;7(10):e737–45. DOI:10.1016/S2352-3026(20)30251-9.
19. Regalado-Artamendi I., JiménezUbieto A., Hernández-Rivas J.Á. et al. Risk factors and mortality of COVID-19 in patients with lymphoma: a multicenter study. Hemasphere 2021;5(3):e538. DOI:10.1097/HS9.0000000000000538.
20. Van Doesum J., Chinea A., Pagliaro M. et al. Clinical characteristics and outcome of SARS-CoV-2-infected patients with haematological diseases: a retrospective case study in four hospitals in Italy, Spain and the Netherlands. Leukemia 2020;34(9):2536–8. DOI:10.1038/s41375-020-0960-4.
21. Lamure S., Dulery R., Delord M. et al. High incidence of persistent COVID-19 among patients with lymphoma treated with B-cell depleting immunotherapy. Clin Cancer Res 2021;27(6):S09–2. DOI:10.1158/1557-3265.COVID-1921-S09-02.
22. Scarfò L., Chatzikonstantinou T., Rigolin G.M. et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia 2020;34(9):2354–63. DOI:10.1038/s41375-020-0959-x.
23. Treon S.P., Castillo J.J., Skarbnik A.P. et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood 2020;135(21):1912–5. DOI:10.1182/blood.2020006288.
24. Isidori A., de Leval L., Gergis U. et al. Management of patients with hematologic malignancies during the COVID-19 pandemic: practical considerations and lessons to be learned. Front Oncol 2020;10:1439. DOI:10.3389/fonc.2020.01439.
25. Anti-CD20 Monoclonal Antibodies and Risk of Severe COVID-19 Infection and Death in Patients With Lymphoma. American Association for Cancer Research (AACR), Virtual Meeting Discussion, 2021. Available at: https://ascopost.com/issues/march-10-2021/anti-cd20monoclonal-antibodies-and-risk-ofsevere-covid-19-infection-and-death-inpatients-with-lymphoma/.
26. ASH: COVID-19 and Indolent Lymphomas: Frequently Asked Questions. Available at: https://www.hematology.org/covid-19/covid-19-and-indolentlymphomas.
27. FAI2R/SFR/SNFMI/SOFREMIP/CRI/ IMIDIATE consortium and contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis 2020;80(4):527–38. DOI:10.1136/annrheumdis-2020-218310.
28. Avouac J., Drumez E., Hachulla E. et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol 2021;3(6):e419–26. DOI:10.1016/S2665-9913(21)00059-X.
29. Garcia-Fernandez A., Lopez-Gutierrez F., Loarce-Martos J. et al. Cohort of rheumatic patients treated with rituximab and COVID-19: does rituximab treatment increases the severity of SARS-COV2 infection? [abstract]. Arthritis Rheum 2020;72(suppl 10).
30. Schulze-Koops H., Krueger K., Vallbracht I. et al. Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Ann Rheum Dis 2021;80(5):e67. DOI:10.1136/annrheumdis-2020-218075.
31. Esmaeili S., Abbasi M.H., Abolmaali M. et al. Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD. BMC Neurol 2021;21(1):183. DOI:10.1186/s12883-021-02218-4.
32. Strangfeld A., Schäfer M., Gianfrancesco M.A. et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2021;80(7):930–42. DOI:10.1136/annrheumdis-2020-219498.
33. Quartuccio L., Treppo E., Binutti M. et al. Timing of rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis. Rheumatology (Oxford) 2021;60(7):3476–7. DOI:10.1093/rheumatology/keab175.
34. Бекетова Т.В., Бабак В.В., Супрун М.Д. Течение и исходы COVID-19 у пациентов с АНЦА-ассоциированными системными васкулитами, получающих лечение генно-инженерными биологическими препаратами (ритуксимаб, меполизумаб): итоги первых 8 месяцев пандемии. Научно-практическая ревматология 2021;59(1):37–46. DOI:10.47360/1995-4484-2021-37-46.
35. Tepasse P.R., Hafezi W., Lutz M. et al. Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. Br J Haematol 2020;190(2):185–8. DOI:10.1111/bjh.16896.
36. Hoffmann M.S., Ganguly S. Delayed COVID-19 respiratory failure in patients with lymphoma on rituximab-based chemoimmunotherapy. Clin Lymphoma Myeloma Leuk 2021;21(6):e548–50. DOI:10.1016/j.clml.2021.02.009.
37. Gelinck L.B., Teng Y.K., Rimmelzwaan G.F. et al. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 2007;66(10):1402–3. DOI:10.1136/ard.2007.071878.
38. Yri O.E., Torfoss D., Hungnes O. et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood 2011 Dec 22;118(26):6769–71. DOI:10.1182/blood-2011-08-372649.
39. Van Assen S., Holvast A., Benne C.A. et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010;62(1):75–81. DOI:10.1002/art.25033.
40. Eisenberg R.A., Jawad A.F., Boyer J. et al. Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol 2013;33(2):388–96. DOI:10.1007/s10875-012-9813-x.
41. Bedognetti D., Zoppoli G., Massucco C. et al. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin’s lymphoma patients treated with rituximabcontaining regimens. J Immunol 2011;186(10):6044–55. DOI:10.4049/jimmunol.1004095.
42. Salles G., Seymour J.F., Offner F. et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377(9759):42–51. DOI:10.1016/S0140-6736(10)62175-7.
43. Wang M., Salles G., Kumar A. et al. Role of maintenance rituximab after first-line bendamustine + rituximab or R-CHOP in patients with mantle cell lymphoma from a large US real-world cohort. Hematological Oncology. Supplement: 16th International Conference on Malignant Lymphoma, Virtual Edition 2021;39(S2):18–22. DOI:10.1002/hon.61_2880.
44. Graf S.A., Stevenson P.A., Holmberg L.A. et al. Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. Ann Oncol 2015;26(11):2323–8. DOI:10.1093/annonc/mdv364.
45. Bose G., Galetta K. Reactivation of SARS-CoV-2 after rituximab in a patient with multiple sclerosis. Mult Scler Relat Disord 2021;52:102922. DOI:10.1016/j.msard.2021.102922.
46. Lancman G., Mascarenhas J., Bar-Natan M. Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia. J Hematol Oncol 2020;13(1):131. DOI:10.1186/s13045-020-00968-1.
47. Devauchelle-Pensec V., Morvan J., Rat A.C. et al. Effects of rituximab therapy on quality of life in patients with primary Sjögren’s syndrome. Clin Exp Rheumatol 2011;29(1):6–12.
48. Colucci M., Carsetti R., Cascioli S., et al. B Cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J Am Soc Nephrol 2016;27(6):1811–22. DOI:10.1681/ASN.2015050523.
49. Dunleavy K., Hakim F., Kim H.K. et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 2005;106(3):795–802. DOI:10.1182/blood-2004-08-3198.
50. Bingham C.O.3rd, Looney R.J., Deodhar A. et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010; 62(1):64–74. DOI:10.1002/art.25034.
51. Hoyer B.F., Manz R.A., Radbruch A., Hiepe F. Long-lived plasma cells and their contribution to autoimmunity. Ann N Y Acad Sci 2005;1050:124–33. DOI:10.1196/annals.1313.014.
52. Nakou M., Katsikas G., Sidiropoulos P. et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther 2009;11(4):R131. DOI:10.1186/ar2798.
53. Takata T., Suzumiya J., Ishikawa T. et al. Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP. J Clin Exp Hematop 2009;49(1):9–13. DOI:10.3960/jslrt.49.9.
54. Quinti I., Lougaris V., Cinzia Milito C. et al. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. J All Clin Immunol 2020;146(1):211–3.e4. DOI:10.1016/j.jaci.2020.04.013.
55. Soresina A., Moratto D., Chiarini M. et al. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr Allergy Immunol 2020;31(5):565–9. DOI:10.1111/pai.13263.
56. Bercovici N., Duffour M.T., Agrawal S. et al. New methods for assessing T-cell responses. Clin Diagn Lab Immunol 2000;7(6):859–64. DOI:10.1128/CDLI.7.6.859-864.2000.
57. Ten Brinke A., Marek-Trzonkowska N., Mansilla M.J. et al. Monitoring T-cell responses in translational studies: optimization of dye-based proliferation assay for evaluation of antigen-specific responses. Front Immunol 2017;8:1870. DOI:10.3389/fimmu.2017.01870.
58. Re D., Barrière J., Chamorey E. et al. Low rate of seroconversion after mRNA antiSARS-CoV-2 vaccination in patients with hematological malignancies. Leuk Lymphoma 2021;62(13):3308–10. DOI:10.1080/10428194.2021.1957877.
59. Herishanu Y., Avivi I., Aharon A. et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood 2021;137(23):3165–73. DOI:10.1182/blood.2021011568.
60. Chilimuri S., Mantri N., Zahid M., Sun H. COVID-19 vaccine failure in a patient on rituximab therapy. Rheumatol Adv Pract 2021;5(2):rkab038. DOI:10.1093/rap/rkab038.
61. Teh B.W., Tam C.S. Between a rock and a hard place: COVID-19 vaccination and patients on rituximab therapy. Leuk Lymphoma 2021;62(12):2820–2. DOI:10.1080/10428194.2021.1957879.
62. Ellwardt E., Ellwardt L., Bittner S., Zipp F. Monitoring B-cell repopulation after depletion therapy in neurologic patients. Neurol Neuroimmunol Neuroinflamm 2018;5(4):e463. DOI:10.1212/NXI.0000000000000463.
63. Thiel J., Rizzi M., Engesser M. et al. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. Arthritis Res Ther 2017;19(1):101. DOI:10.1186/s13075-017-1306-0.
64. Kant S., Kronbichler A., Salas A. et al. Timing of COVID-19 vaccine in the setting of anti-CD20 therapy: a primer for nephrologists. Kidney Int Rep 2021;6(5):1197–9. DOI:10.1016/j.ekir.2021.03.876.
65. Furer V., Rondaan C., Heijstek M.W. et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020;79(1):39–52. DOI:10.1136/annrheumdis-2019-215882.
66. Bonelli M.M., Mrak D., Perkmann T. et al. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response. Ann Rheum Dis 2021;80(10):1355–6. DOI:10.1136/annrheumdis-2021-220408.
67. Kamar N., Abravanel F., Marion O. et al. Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients. N Engl J Med 2021;385(7):661–2. DOI:10.1056/NEJMc2108861.
68. Hill J.A., Ujjani C.S., Greninger A.L. et al. Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient. Cancer Cell 2021;39(8):1037–8. DOI:10.1016/j.ccell.2021.06.015.
69. Graalmann T., Borst K., Manchanda H. et al. B cell depletion impairs vaccinationinduced CD8+ T cell responses in a type I interferon-dependent manner. Ann Rheum Dis 2021;80(12):1537–44. DOI:10.1136/annrheumdis-2021-220435.
70. Monin L., Laing A.G., Muñoz-Ruiz M. et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol 2021;22(6):765–78. DOI:10.1016/S1470-2045(21)00213-8.
71. Mehta P., Porter J.C., Chambers R.C. et al. B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand? Lancet Rheumatol 2020;2(10):e589–90. DOI:10.1016/S2665-9913(20)30270-8.
72. Zhao J., Yuan Q., Wang H. et al. Antibodyresponses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis 2020;71(16):2027–34. DOI:10.1093/cid/ciaa344.
73. Woodruff M.C., Ramonell R.P., Cashman K.S. et al. Critically ill SARS-CoV-2 patients display lupus-like hallmarks of extrafollicular B cell activation. medRxiv 2020. DOI:10.1101/2020.04.29.20083717.
74. Iwasaki A., Yang Y. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol 2020;20:339–41. DOI:10.1038/s41577-020-0321-6.
75. Mehta P., McAuley D.F., Brown M. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229):1033–4. DOI:10.1016/S0140-6736(20)30628-0.
76. Fill L., Hadney L., Graven K. et al. The clinical observation of a patient with common variable immunodeficiency diagnosed as having coronavirus disease 2019. Ann Allergy Asthma Immunol 2020;125(1):112–4. DOI:10.1016/j.anai.2020.04.033.
77. Wen X.S., Jiang D., Gao L. et al. Clinical characteristics and predictive value of lower CD4+T cell level in patients with moderate and severe COVID-19: a multicenter retrospective study. BMC Infect Dis 2021;21(1):57. DOI:10.1186/s12879-020-05741-w.
78. Liu Z., Long W., Tu M. et al. Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19. J Infect 2020;81(2):318–56. DOI:10.1016/j.jinf.2020.03.054.
79. García Muñoz R., Izquierdo-Gil A., Muñoz A. et al. Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent nonHodgkin lymphomas treated with bendamustine plus rituximab. Ann Hematol 2014;93(11):1879–87. DOI:10.1007/s00277-014-2135-8.
80. Melet J., Mulleman D., Goupille P. et al. Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum 2013;65(11):2783–90. DOI:10.1002/art.38107.
81. Kravchenko S., Sychevskaya K., Babaeva F., Misurina A. High risk of COVID-19 associated mortality in follicular lymphoma patients on antiCD20 maintenance. The 83rd Annual Meeting of the Japanese Society of Hematology. Book of Abstracts. Best Poster Award Session. 2021. P. 661.
Рецензия
Для цитирования:
Сычевская К.А., Кравченко С.К. Применение моноклональных анти-CD20-антител в терапии лимфом в условиях пандемии COVID-19: за и против. Онкогематология. 2022;17(2):95-106. https://doi.org/10.17650/1818-8346-2022-17-2-95-106
For citation:
Sychevskaya K.A., Kravchenko S.K. Monoclonal anti-CD20 antibodies in lymphomas therapy during the COVID-19 pandemic: pro and contra. Oncohematology. 2022;17(2):95-106. (In Russ.) https://doi.org/10.17650/1818-8346-2022-17-2-95-106
Просмотров:
9243
Послать статью по эл. почте 